Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 235

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 235
---
75
million and to include Aegeria and Cerevast as the Target Acquisitions.

On July 3, 2024, Longevity
presented certain financial projections and models to FutureTech to assist in its due diligence of the proposed valuation and
of Longevity generally.

On July 8, 2024,
Mr. Ray Chen, Mr. Bradford A. Zakes, Ms. Brenda Sparks, and Mr. Ying Shan met to discuss the financial projections and models and to address
FutureTech’s questions. A discussion of the funding of the proposed business combination was also had.

On July 10, 2024,
Mr. Ray Chen, Mr. Bradford A. Zakes, Ms. Brenda Sparks, and Mr. Ying Shan met to discuss a possible PIPE transaction, including potential
terms and structures.

On July 11, 2024,
Mr. Ray Chen, Mr. Bradford A. Zakes, Ms. Brenda Sparks, Mr. Ying Shan, and Nelson Mullins met to discuss the proposed business combination
and the funding needed to complete it.

On July 12, 2024,
FutureTech entered into a letter of Intent with Longevity to commence preliminary discussions with Longevity and commence an initial due
diligence.

On July 15, 2024, FutureTech engaged
Moses & Singer LLP (“Moses Singer”) as counsel in connection with the proposed business combination.

On July 19, 2024,
representatives of Longevity and representatives of Aegeria met to discuss the proposed business combination with FutureTech.

On July 22, 2024,
Longevity circulated a draft merger agreement to FutureTech for review. On July 23, 2024, Mr. Ray Chen, Mr. Bradford A. Zakes, Ms. Brenda
Sparks, Mr. Ying Shan and Mr. Yuquan Wang met to discuss next steps regarding the transaction and timing.

On July 22, 2024, the FutureTech
Board held a meeting to discuss a potential acquisition of Longevity.

On July 26, 2024,
Mr. Ray Chen, Mr. Bradford A. Zakes, Ms. Brenda Sparks, Mr. Ying Shan and representatives of Newbridge Securities Corporation (“Newbridge”)
met to discuss Newbridge’s process for conducting valuation analyses of the Target Acquisition and the proposed business combination
and providing a fairness opinion regarding the proposed business combination.

On July 31, 2024,
representatives of Longevity met with the